Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
$1.70
-6.1%
$2.37
$1.43
$4.84
$16.01M0.32320,183 shs221,149 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
0.00%-3.41%-31.45%-23.08%-50.87%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
1.3551 of 5 stars
0.05.00.00.03.41.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
$60K266.76N/AN/A$0.43 per share3.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
-$5.36M-$0.86N/AN/AN/A-141.39%-124.63%4/4/2025 (Estimated)

Latest BFRG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2025Q4 2024
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/A-$0.18N/A-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/A
5.90
5.90

Institutional Ownership

CompanyInstitutional Ownership
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
0.96%

Insider Ownership

CompanyInsider Ownership
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
33.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
49.42 million5.76 millionNot Optionable

Recent News About These Companies

Can BullFrog AI Continue to Leap Higher?
Bullfrog AI to present at Biotech Showcase and RESI JPM
BullFrog AI Issues Letter to Stockholders
20 AI News Investors Should Not Miss
Bullfrog AI to present at Google’s Cancer AI Symposium

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bullfrog AI stock logo

Bullfrog AI NASDAQ:BFRG

$1.70 -0.11 (-6.08%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$1.70 +0.01 (+0.29%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.